A Swedish biopharmaceutical company in-licensed three drugs for commercialization in the U.S. and Canada. With no infrastructure in North America, the company needed to immediately ramp up an operational team. Through a tailored partnership, Quintiles and Sobi worked closely together to develop and execute an effective commercial strategy. Quintiles provided the complete commercial infrastructure and local market knowledge and expertise to establish Sobi’s position in the U.S. market and also manage the existing business in Canada.

The partnership achieved double-digit growth for the new drug acquisitions during the project and Sobi retained control as the North American infrastructure was developed in preparation for a seamless transfer to Sobi as a wholly owned subsidiary.